Skip to main content
letter
. 2006 Nov 7;95(11):1455–1458. doi: 10.1038/sj.bjc.6603456

Figure 2.

Figure 2

Survival of patients with bladder cancer according to variants of the FGFR Gly388Arg polymorphism. Log-rank analyses of the association between FGFR4 genotypes and (A) recurrence-free survival time and (B) metastasis-free survival time in bladder cancer.